Alzheimer’s disease clinical decision points for two plasma p-tau217 laboratory developed tests in neuropathology confirmed samples DOI Creative Commons
Anna Mammel, Ging‐Yuek Robin Hsiung,

Ali Mousavi

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: July 29, 2024

ABSTRACT INTRODUCTION We evaluated the diagnostic performance of two commercial plasma p-tau217 immunoassays compared to CSF testing and neuropathology. METHODS 170 samples from University British Columbia Hospital Clinic for Alzheimer’s (AD) Related Disorders were analyzed using Fujirebio ALZpath assays. Decision points determined autopsy findings as standard. RESULTS had similar overall analytical clinical performance, with distinct decision each assay. Based on finding, both assays identified individuals AD other neurodegenerative diseases (ALZpath AUC = 0.94, AUC= 0.90). The assay detected pathology at milder disease stages DISCUSSION Our study reinforces utility an biomarker. Differences in test suggest specific approach is required practice.

Language: Английский

Plasma p‐tau217 and p‐tau217/Aβ1‐42 are effective biomarkers for identifying CSF‐ and PET imaging‐diagnosed Alzheimer's disease: Insights for research and clinical practice DOI Creative Commons
Xiaomei Zhong, Qiang Wang, Mingfeng Yang

et al.

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Abstract INTRODUCTION With the advancement of disease‐modifying therapies for Alzheimer's disease (AD), validating plasma biomarkers against cerebrospinal fluid (CSF) and positron emission tomography (PET) standards is crucial in both research real‐world settings. METHODS We measured phosphorylated tau (p‐tau)217, p‐tau181, amyloid beta (Aβ)1‐40, Aβ1‐42, neurofilament light chain cohorts. Participants were categorized by brain status using US Food Drug Administration/European Medicines Agency–approved CSF or PET methods. RESULTS Plasma p‐tau217 p‐tau217/Aβ1‐42 demonstrated superior accuracy detecting pathologies, with area under curve from 0.94 to 0.97 all Specificity was lower cohort but improved significantly integrating demographic clinical factors, aligning performance Additionally, exhibited strong correlations their counterparts standardized uptake value ratios, significant associations amyloid‐positive participants. DISCUSSION are effective diagnostic tools. However, patient demographics, apolipoprotein E ε4 status, cognitive condition must be considered improve specificity practice. Highlights (p‐tau)217 p‐tau217/amyloid (Aβ)1‐42 exceptional (area curve: 0.94–0.97) pathologies across (Southern China Aging Brain Initiative [SCABI]‐1, SCABI‐2) practice (RCP) Incorporating patient‐specific factors (sex, age, ε4, status) RCP cohort, its that biomarkers, particularly showed robust underscoring as non‐invasive alternatives. proved highly diagnosing burden, offering a practical solution bridge advancements

Language: Английский

Citations

1
Clinical decision points for two plasma p‐tau217 laboratory developed tests in neuropathology confirmed samples DOI Creative Commons
Anna Mammel, Ging‐Yuek Robin Hsiung,

Ali Mousavi

et al.

Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 1, 2025

Language: Английский

Citations

0
Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer’s disease: a real-world study DOI
Giordano Cecchetti, Federica Agosta, Giulia Rugarli

et al.

Journal of Neurology, Journal Year: 2024, Volume and Issue: 271(10), P. 6739 - 6749

Published: Aug. 22, 2024

Language: Английский

Citations

3
Core blood biomarkers of Alzheimer's disease: A single-center real-world performance study DOI Creative Commons
Federico Emanuele Pozzi,

Elisa Conti,

Giulia Remoli

et al.

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2025, Volume and Issue: 12(2), P. 100027 - 100027

Published: Jan. 23, 2025

Language: Английский

Citations

0
Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer’s disease DOI Open Access
Giordano Cecchetti, Federica Agosta, Giulia Rugarli

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: May 20, 2024

Abstract INTRODUCTION Considerable advancements have occurred in blood-based Alzheimer’s disease (AD) biomarkers, with automated assays emerging for clinical use. Demonstrating the reliability of these systems is crucial upcoming AD therapies. METHODS This cross-sectional study a Memory Center enrolled 98 patients along continuum or affected by other neurodegenerative disorders, stratified CSF A/T status and syndrome. Plasma pTau-217, pTau-181, Aβ42/Aβ40 were measured using Lumipulse. Relationships glomerular filtration rate (GFR) explored. ROC analysis was conducted to assess diagnostic performance. RESULTS GFR effect lowered use ratios pTau-217 correlation strong. discriminated A+/T+ excellent accuracy both dementia mild cognitive impairment (AUC 0.93-0.97), outperforming pTau-181 Aβ42/Aβ40. Cutoffs displayed high DISCUSSION Lumipulse identified cutoffs exhibit group detection, facilitating future translation.

Language: Английский

Citations

2
P-tau217 as a Reliable Blood-Based Marker of Alzheimer’s Disease DOI Creative Commons

Roy Lai,

Brenden Li,

Ram Bishnoi

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(8), P. 1836 - 1836

Published: Aug. 13, 2024

Amyloid plaques and tau tangles are the hallmark pathologic features of Alzheimer’s disease (AD). Traditionally, these changes identified in vivo via cerebrospinal fluid (CSF) analysis or positron emission tomography (PET) scans. However, methods invasive, expensive, resource-intensive. To address limitations, there has been ongoing research over past decade to identify blood-based markers for AD. Despite challenges posed by their extremely low concentrations, recent advances mass spectrometry immunoassay techniques have made it feasible detect blood amyloid deposition. Phosphorylated (p-tau) shown greater promise reflecting pathology as evidenced CSF PET positivity. Various isoforms p-tau, distinguished differential phosphorylation sites, recognized ability amyloid-positive individuals. Notable examples include p-tau181, p-tau217, p-tau235. Among these, p-tau217 emerged a superior reliable marker positivity and, thus, AD terms accuracy diagnosis early prognosis. In this narrative review, we aim elucidate utility an marker, exploring its underlying basis, clinical diagnostic potential, relevance care trials.

Language: Английский

Citations

2
Alzheimer’s disease clinical decision points for two plasma p-tau217 laboratory developed tests in neuropathology confirmed samples DOI Creative Commons
Anna Mammel, Ging‐Yuek Robin Hsiung,

Ali Mousavi

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: July 29, 2024

ABSTRACT INTRODUCTION We evaluated the diagnostic performance of two commercial plasma p-tau217 immunoassays compared to CSF testing and neuropathology. METHODS 170 samples from University British Columbia Hospital Clinic for Alzheimer’s (AD) Related Disorders were analyzed using Fujirebio ALZpath assays. Decision points determined autopsy findings as standard. RESULTS had similar overall analytical clinical performance, with distinct decision each assay. Based on finding, both assays identified individuals AD other neurodegenerative diseases (ALZpath AUC = 0.94, AUC= 0.90). The assay detected pathology at milder disease stages DISCUSSION Our study reinforces utility an biomarker. Differences in test suggest specific approach is required practice.

Language: Английский

Citations

0